Atezolizumab vs Durvalumab in Small Cell Lung Cancer

Neither is standard over the other. For extensive-stage disease, NCCN lists both — atezolizumab with carboplatin and etoposide, and durvalumab with etoposide plus carboplatin or cisplatin — as category 1 preferred first-line options. Limited-stage disease is where the answer separates: durvalumab has an approved role after concurrent chemoradiotherapy. Atezolizumab does not.

This is the part that most comparison pages get wrong. They ask which drug is better and produce a winner. The guideline bodies that reviewed the same evidence declined to do that, and put both at the same level of recommendation instead.

So the useful question is not which drug ranks higher. It is which one the label allows for your stage, which platinum drug you can safely receive, and what your treating hospital's protocol runs. Those three things settle almost every real case before any comparison of the molecules is needed.

Both are given as day-care intravenous infusions alongside chemotherapy. Neither is a tablet, and neither is taken at home.

They block the same protein. Both are anti-PD-L1 antibodies, so the mechanism is not what separates them — unlike pembrolizumab or nivolumab, which block PD-1 on the T cell. The differences sit in the approved stage, the platinum partner allowed, the dosing interval and the Indian regulatory history.

Read the table as the shape of the system, not as your eligibility. Approved wording differs between markets, changes over time, and the current Indian package insert governs — not this page.

No randomised trial has compared them head to head in small cell lung cancer. Each was tested against chemotherapy alone in its own study — atezolizumab in IMpower133, durvalumab in CASPIAN. The two trial populations were similar but not identical, which is exactly why the results cannot be laid side by side and read as a contest.

Guideline panels reviewing both bodies of evidence placed them at the same level of recommendation. That is the closest thing to a verdict that exists, and it is a deliberate one.

Retrospective and registry comparisons have been published and are sometimes quoted in consultations. They are not randomised. The patients in them were not assigned by chance, so differences in who received which drug — age, fitness, centre, year of treatment — sit inside any difference in result. No guideline recommendation rests on them, and no figure from them is reproduced here, because a number of that kind attached to a treatment decision would mislead more than it informs.

If a specific percentage has been quoted to you for either drug, ask which trial it came from, which population it described, and whether it applies to your stage. That single question changes most conversations.

Usually because only one of the two was actually available as an option for your situation. The stage of the disease, the platinum drug you can tolerate, the current approved indication in India, and the hospital's protocol narrow the field before any comparison of the molecules begins.

Four things do most of the work:

• Stage. Limited-stage disease after chemoradiotherapy points to durvalumab, because that is where its approved role sits. Extensive-stage disease keeps both in view.
• Which platinum you can receive. The durvalumab regimen is worded to allow cisplatin or carboplatin. The atezolizumab regimen is worded around carboplatin. If cisplatin is preferred in your case, or if kidney function or hearing rules cisplatin out, that alone can decide the pairing.
• The Indian label on the day. Indications are approved and extended on a rolling basis, and the Indian list is not a copy of the US or EU list. What was true last year may not be true now.
• Protocol and supply. Hospitals standardise on regimens they can run and stock reliably. That is a legitimate clinical-governance reason, not a commercial one, and it is worth asking about openly.

The same logic — label first, molecule second — governs comparisons elsewhere in this class. For how a PD-1 drug and a PD-L1 drug differ where both are on the table, see Pembrolizumab vs Nivolumab: What Is the Difference?, and for a comparison where the tumour type rather than the target drives the choice, see Cemiplimab vs Pembrolizumab for Skin Cancer.

Both remain high-cost originator biologics, and as of August 2026 neither has an approved Indian biosimilar. There is no dependable published list price for either that would allow an honest like-for-like comparison — quotes on pharmacy marketplaces for the same vial vary several-fold, which tells you they are listings, not prices.

That is an uncomfortable answer, and it is the accurate one. Saying that one drug costs less than the other, on the evidence publicly available in India, would be inventing a figure.

What can be said usefully is what moves the total:

• Vials per dose. Both are given as fixed doses rather than by body weight in adults, so the vial count per dose is predictable once the regimen is set.
• Number of chemotherapy cycles. The induction phase of both regimens is a defined number of cycles; maintenance is what continues afterwards, and for how long is the larger variable.
• Maintenance interval. A four-weekly maintenance schedule means fewer day-care visits in a year than a three-weekly one. That reduces day-care and travel charges, though not necessarily the drug cost itself.
• Which platinum is used. Cisplatin usually needs more hydration and monitoring than carboplatin, which changes the supportive-care side of the bill.

One dated, published data point is worth naming rather than a rate card: Roche India's launch of a subcutaneous form of atezolizumab was reported in the Indian national press in May 2026 at approximately ₹3.7 lakh per dose. No comparable published Indian figure for durvalumab could be verified when this page was written, so the two cannot responsibly be compared on price. Any figure anywhere is indicative, as of August 2026.

Ask the hospital pharmacy for a written, per-cycle estimate for the exact regimen proposed, and ask separately what it becomes if maintenance continues past a year. For how originator and Indian brand pricing actually diverge once a biosimilar does arrive, see Keytruda vs Opdyta: Cost and Indications in India.

Broadly, no. Both release the same immune brake, so both can trigger the same family of immune-related adverse events — inflammation of the thyroid, gut, lungs, liver, skin, joints or, less often, the heart and adrenal glands. Neither has a meaningfully safer profile as a class matter.

In small cell lung cancer there is a second point worth holding onto. Most of what a patient feels in the first few cycles comes from the etoposide and platinum backbone, not from the checkpoint inhibitor. Low blood counts, nausea and hair loss belong to the chemotherapy. Immune-related effects tend to declare themselves later and behave differently — they do not settle on their own the way a chemotherapy side effect often does.

Any new symptom during or after these treatments should be reported to the treating team early, and never managed at home as an ordinary infection or stomach upset. The main immunotherapy section carries the symptom-by-symptom guidance this comparison deliberately does not attempt.

If you want the single-molecule detail rather than the comparison, Atezolizumab (Tecentriq) and Durvalumab (Imfinzi) cover each drug on its own terms. For the wider map of checkpoint inhibitors, biosimilars and how the medicines in this class relate to one another, start at Immunotherapy Medicines Explained. And for the treatment itself — how it is given, who it suits, and what it does not do — see the main immunotherapy section.